Teacher Retirement System of Texas Sells 9,892 Shares of iRadimed Corporation $IRMD

Teacher Retirement System of Texas trimmed its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 24.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,315 shares of the medical equipment provider’s stock after selling 9,892 shares during the period. Teacher Retirement System of Texas owned approximately 0.24% of iRadimed worth $2,157,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of IRMD. CWM LLC lifted its holdings in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of iRadimed during the third quarter worth $47,000. Spire Wealth Management acquired a new position in shares of iRadimed during the second quarter valued at $60,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in iRadimed by 30.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 2,056 shares of the medical equipment provider’s stock valued at $123,000 after acquiring an additional 477 shares during the last quarter. 92.34% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO John Glenn sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This represents a 67.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $100.65, for a total transaction of $503,250.00. Following the sale, the chief executive officer owned 2,262,500 shares in the company, valued at $227,720,625. This trade represents a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 60,000 shares of company stock valued at $5,701,100 over the last 90 days. Corporate insiders own 36.80% of the company’s stock.

iRadimed Price Performance

iRadimed stock opened at $97.88 on Friday. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of 59.32 and a beta of 1.09. The company’s 50 day simple moving average is $97.35 and its 200 day simple moving average is $81.09. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $104.93.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, analysts predict that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is presently 41.21%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IRMD. Roth Mkm set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research note on Monday, November 3rd. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.